Swiss-Italian startup Ferm Labs secures €3 million to scale its bioprocessing-based B2B ingredient platform
Ferm Labs, a Zug-based ingredient startup specialising in proprietary, high-yield bioprocessing platforms, has secured €3 million to scale its bioprocessing platform across the global clean-label ingredient market. The round was led by CDP Venture Capital (through its Green Transition Fund/NextGenerationEU), alongside a syndicate of European investors including Fund F, Redstone (in collaboration…
Swiss-Italian biotech startup Ferm Labs has secured €3 million in funding to expand its bioprocessing-based ingredient platform for the global clean-label market. The investment, led by CDP Venture Capital through its Green Transition Fund/NextGenerationEU and a group of European investors, will support the company's scaling efforts in manufacturing and European expansion.
Founded in 2025 by Stephanie Lüpold and Mattia Baroni, Ferm Labs focuses on developing high-yield, clean-label B2B flavour systems for the food industry. Their proprietary platform accelerates fermentation time, upcycles low-value sidestreams into kokumi peptide profiles, and eliminates the trade-off between synthetic additives and costly natural ingredients.
The company's flagship product, Kokumesan, a kokumi peptide profile made from liquid whey, targets the US/European industrial cheese market and offers 75% Cost-in-Use savings for manufacturers. Ferm Labs plans to use the funding to increase bioprocessing capacity in South Tyrol, grow its European B2B sales force, and expand its R&D team for new product categories.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
